Form 4: Director Devdatt Kurdikar Acquires ZBH Phantom Stock

Zimmer Biomet Holdings Director Devdatt Kurdikar reported the acquisition of 152.22 phantom stock units, increasing his total beneficial ownership to 1,769.983 units.

Summary

• Director Devdatt Kurdikar acquired 152.22 phantom stock units of Zimmer Biomet Holdings, Inc. (ZBH) on December 31, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Each phantom stock unit is convertible on a 1-for-1 basis into shares of the company's common stock.
• Following this transaction, Kurdikar beneficially owns a total of 1,769.983 phantom stock units.
• The total beneficial ownership includes 3.876 phantom stock units accrued on October 31, 2025, through the dividend reinvestment provision of the Deferred Compensation Plan.

Sentiment

Score: 6

Explanation: The acquisition of phantom stock units by a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. However, as a routine compensation event, it is not a strong indicator of immediate operational performance or a significant strategic shift, thus warranting a moderate positive score.

Positives

• Director Devdatt Kurdikar increased his beneficial ownership in Zimmer Biomet Holdings, Inc. by acquiring 152.22 phantom stock units.
• The acquisition of phantom stock units aligns the director's financial interests with long-term shareholder value and company performance.

Future Outlook

The phantom stock units are scheduled to be settled in shares of Zimmer Biomet Holdings, Inc. common stock within sixty days after the reporting person's cessation of service as a Director.

Industry Context

This filing represents a routine insider transaction report, which is a common occurrence in the medical device industry. It reflects a director's participation in a deferred compensation plan, a standard practice designed to align the interests of company leadership with long-term shareholder value and overall company performance.

Comparison to Industry Standards

• The use of phantom stock units as a component of non-employee director compensation is a widely adopted practice across various industries, including medical technology.
• Leading companies such as Stryker Corporation (SYK) and Johnson & Johnson (JNJ) also employ similar equity-based compensation structures to attract, retain, and incentivize their directors, fostering alignment with shareholder interests.
• The 1-for-1 conversion ratio of phantom stock units to common stock is a standard feature within such compensation plans, ensuring direct correlation with the underlying equity value.

Stakeholder Impact

• Shareholders: The transaction enhances the alignment of a director's financial interests with those of the shareholders, potentially fostering more shareholder-centric decision-making.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Settlement of the phantom stock units into common stock shares within 60 days after Devdatt Kurdikar ceases service as a Director.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by a director as part of a deferred compensation plan. While it indicates alignment of interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Zimmer Biomet Holdings, ZBH, Phantom Stock Units, Director Compensation, Insider Trading, SEC Form 4, Devdatt Kurdikar, Equity Compensation